Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25492471 | 1.00 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983084 | 1.00 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983092 | 1.00 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL149389 | 1.00 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL23523712 | 0.96 | DNMT1 (0.53) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL27171596 | 0.89 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL7222104 | 0.88 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL9840726 | 0.88 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL7222108 | 0.88 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL8755221 | 0.88 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 965 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20090307805-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | KEYGENE N.V | 2009-12-10 | — | — | US | claimed |
| US-6355785-B1 | ENZYME INHIBITORS | ARONEX PHARMACEUTICALS, INC. | 2002-03-12 | — | — | US | claimed |
| WO-2000028087-A1 | A LIBRARY OF MODIFIED PRIMERS FOR NUCLEIC ACID SEQUENCING, AND METHOD OF USE THEREOF | SEQUETECH CORPORATION (US) | 2000-05-18 | — | — | WO | claimed |
| US-5633360-A | CONTAINS AT LEAST TWO NUCLEOSIDE RESIDUES AND INTERNUCLEOTIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1997-05-27 | — | — | US | claimed |
| EP-0573479-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-15 | — | — | EP | claimed |
| WO-1992015693-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |
| US-5079235-A | 5-Substituted Pyrimidine Nucleosides | BURROUGHS WELLCOME CO. (US) | 1992-01-07 | — | — | US | claimed |
| EP-0272065-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-22 | — | — | EP | claimed |
| US-12618063-B2 | Pan-genotypic agents against influenza virus and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-05 | — | — | US | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12522827-B2 | Pan-genotypic agents against influenza virus and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-01-13 | — | — | US | disclosed |
| WO-1992015693-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | disclosed |
| EP-0486477-A2 | 1-( -D-Arabinofuranosyl)-5-propynyluracil as a VZV-antiviral compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-20 | — | — | EP | disclosed |
| US-5079235-A | 5-Substituted Pyrimidine Nucleosides | BURROUGHS WELLCOME CO. (US) | 1992-01-07 | — | — | US | disclosed |
| EP-0417560-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
| EP-0272065-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | DNMT1 274/4885ADRB1 4500/4885DNMT3B 332/4885 |
| US-12618063-B2 | Pan-genotypic agents against influenza virus and methods of using the same | ADAR, MTAP, PNP | DNMT1 2516/4885ADRB1 1851/4885DNMT3B 1911/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | DNMT1 384/4885ADRB1 4067/4885DNMT3B 303/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | DNMT1 1090/4885ADRB1 2217/4885DNMT3B 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.